Truist Lowers DexCom (DXCM) PT to $94 Ahead of Q3 MedTech Sector Preview, Maintains Buy Rating

DexCom Inc. (NASDAQ:DXCM) is one of the best NASDAQ growth stocks to buy for the next 5 years. On October 15, Truist analyst Richard Newitter lowered the firm’s price target on DexCom to $94 from $102 with a Buy rating on the shares as part of the firm’s broader research note previewing Q3 2025 results in the MedTech sector. The firm anticipates healthy revenue and earnings for Q3 across all companies it covers, but warns of stock volatility.

Furthermore, on October 21, Stifel resumed coverage on several MedTech companies due to an optimistic view on the sector’s growth, driven by the adoption of continuous glucose monitors/CGMs and insulin pumps. The firm particularly highlighted a long-term growth opportunity for the CGM market within the substantial Type 2 Basal-only and Type 2 Non-insulin patient segments. This is the same reason Stifel initiated coverage on DexCom.

DexCom Inc. (NASDAQ:DXCM) is a medical device company that designs, develops, and commercializes continuous glucose monitoring/CGM systems in the US and internationally.

While we acknowledge the potential of DXCM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.